SOST and stroke disorder: Humanized antibody against sclerostin for postmenopausal osteoporosis therapy was approved by the U.S. Food and Drug Administration (FDA) in April 2019, with a boxed warning on its labelling stating that this treatment may increase the risk of heart attack, stroke and cardiovascular death and should not be used in patients who have had a heart attack or stroke within one year.